Media Thread, page-16947

LOS ALTOS, Calif., Dec. 11, 2024 -- RenovoRx, Inc. (Nasdaq: RNXT), announced today that SCRI Oncology Partners in Nashville, TN, is now enrolling patients with locally advanced pancreatic cancer (LAPC) in the Company’s ongoing pivotal Phase III TIGeR-PaC clinical trial. SCRI Oncology Partners joins esteemed clinical sites throughout United States participating in the study.
“On an annual basis, SCRI and its affiliated sites reach one in five patients with cancer and is responsible for enrolling thousands of patients on clinical trials,” said Leesa Gentry, Chief Clinical Officer of RenovoRx. “We believe this collaboration will assist the Company in both accelerating patient enrollment in our pivotal Phase III TIGeR-PaC clinical trial and driving the study towards its expected enrollment completion in the first half of 2025. Dr. Pelster’s significant expertise and inspiring leadership, coupled with the world-class capabilities at SCRI, will be instrumental in driving TIGeR-PaC’s completion forward.”

SCRI Oncology Partners is the most recent clinical trial sites to join the Phase III TIGeR-PaC study. As part of SCRI, one of the world’s leading oncology research organizations conducting community-based clinical trials, their mission is to advance therapies and expand access to clinical trials to patients closer to home. Today, the SCRI research network includes more than 250 locations across 24 states in the U.S.

About Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 800 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. SCRI’s research network brings together more than 1,300 physicians who are actively enrolling patients into clinical trials at more than 250 locations in 24 states across the U.S

I would like to remind IMU shareholders about the announcement from Renovo on June 10, 2024.

“I am thrilled to officially welcome Ryan as our new Senior Vice President, Head of Corporate Strategy and Partnerships,” said Shaun Bagai, CEO of RenovoRx. “Ryan brings extensive corporate strategy and operational experience to this role at RenovoRx. He has already provided important value to our efforts, and we are excited to continue to leverage his expertise as we advance our pivotal Phase III clinical trial, expand development opportunities into additional cancers and explore new commercial business development opportunities with our therapeutic technology.”

“RenovoRx is at an important juncture, and I am excited to step into this role on a permanent basis,” said Mr. Witt. “Building off our collaboration with Imugene and clinical data delivering gemcitabine with our drug-delivery platform, there is incredible potential for RenovoRx’s technology. This is particularly apparent after my experience at Immix and working with over 200 leading Stanford-affiliated companies at StartX. I look forward to pulling from my experience in medical technology and biopharmaceuticals to help RenovoRx realize this opportunity in the form of better outcomes for patients and increased shareholder value.”

We trade our beliefs & I believe Imugene is in the thick of it here, just waiting for their opportunity to prove/disproveCF33 & as such is pure speculation on my part.
imo dyor